Responses
Behcet’s disease
Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet’s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial
Compose a Response to This Article
Other responses
No responses have been published for this article.